Article
Targeting tauopathy with engineered tau-degrading intrabodies.
Molecular neurodegeneration - 22 Oct 2019
Gallardo Gilbert, Wong Connie H, Ricardez Sara M, Mann Carolyn N, Lin Kent H, Leyns Cheryl E G, Jiang Hong, Holtzman David M
Abstract excerpt
BACKGROUND: The accumulation of pathological tau is the main component of neurofibrillary tangles and other tau aggregates in several neurodegenerative diseases, referred to as tauopathies. Recently, immunotherapeutic approaches targeting tau have been demonstrated to be beneficial in decreasing tauopathy in animal models. We previously found that passive immunotherapy with anti-tau antibody to human tau or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.